29
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9928 |
Ranibizumab
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Ranibizumab 是一种人源化单克隆抗体片段,旨在靶向和抑制血管内皮生长因子 (VEGF),包括 VEGF110、VEGF121 和 VEGF165。 Ranibizumab 选择性靶向和中和 VEGF-A 同工型的能力使其成为湿性年龄相关性黄斑变性 (AMD) 研究和治疗策略的重要组成部分。 | |||
T28273L |
OT-551 HCl
OT-551 HCl(627085-11-4 Free base) |
NF-κB | NF-κB |
OT-551 HCl 是一种 NF-Κb 抑制剂,是一种具有抗氧化特性的二取代羟胺可用于治疗白内障和老年性黄斑变性和地域性萎缩 (GA)。 | |||
T2706 |
Palomid 529
P529,SG 00529 |
Apoptosis; mTOR | Apoptosis; PI3K/Akt/mTOR signaling |
Palomid 529 (SG 00529) 是一种mTORC1和mTORC2复合体抑制剂,已用于研究治疗年龄相关性黄斑变性的试验。 | |||
T13157 |
TG 100801
TG100801,TG 100572 |
VEGFR; Src | Angiogenesis; Tyrosine Kinase/Adaptors |
TG 100801 是 VEGFr2 和 Src 家族(Src 和 YES)激酶的双重抑制剂,是治疗年龄相关性黄斑变性(AMD)的候选化合物。 | |||
T77600 |
Methyl-4-oxoretinoate
|
Apoptosis | Apoptosis |
Methyl-4-oxoretinoate 是一种合成的类视黄醇化合物,具有抗癌化合物,可可以诱导癌细胞分化和凋亡。Methyl-4-oxoretinoate 可用于治疗痤疮、牛皮癣和其他皮肤病。Methyl-4-oxoretinoate 具有治疗各种眼部疾病(如年龄相关性黄斑变性)的潜力。 | |||
T7493 |
AG-13958
AG-013958,N-[2-氟-5-[[3-[(1E)-2-(2-吡啶基)乙烯基]-1H-吲唑-6-基]氨基]苯基]-1,3-二甲基-1H-吡唑-5-甲酰胺 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
AG-13958 (AG-013958) 是 VEGFR 酪氨酸激酶抑制剂,可用于年龄相关性黄斑变性 (AMD) 的脉络膜新生血管形成的研究。 | |||
T28273 |
OT-551
CPC 551,OT 551,CPC551,CPC-551 |
||
OT-551, a NF-κB inhibitor, is used potentially for the treatment of cataracts and age-related macular degeneration. | |||
T27670 |
JNJ-26076713
JNJ26076713 |
||
JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy. | |||
T71988 | Moxaverine hydrochloride | ||
Moxaverine hydrochloride is a derivative of papaverine, a phosphodiesterase inhibitor. Moxaverine has been studied in phase III of a clinical trial for the treatment of ocular blood flow in patients with age- related macular degeneration and primary open angle glaucoma. | |||
T39706 |
Pegaptanib sodium
|
||
Pegaptanib sodium, an RNA aptamer specifically targeting vascular endothelial growth factor (VEGF)-165, holds great promise for investigating neovascular age-related macular degeneration (AMD). | |||
T9695L |
POT-4 acetate
POT-4 acetate (934461-40-2 free base) |
Complement System | Immunology/Inflammation |
POT-4 acetate 抑制 Complement C3 的活化。 POT-4 acetate 可用于年龄相关性黄斑变性的研究。 | |||
TP1390 |
CEP dipeptide 1
|
||
CEP dipeptide 1, a potent angiogenic compound, exhibits robust activity in promoting angiogenesis. This compound is specifically implicated in the pathogenesis of age-related macular degeneration (AMD). | |||
TP1464 |
Risuteganib hydrochloride
|
||
Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retin | |||
T77016 | Galegenimab | ||
Galegenimab (FHTR 2163; RG 6147; RO 7171009),一种抗 HTRA1抗体片段。Galegenimab 可用于年龄相关性黄斑变性 (AMD) 研究。 | |||
T74867 |
UBX1325
|
||
UBX1325 是一种Bcl-xL 抑制剂,可促进衰老细胞的凋亡 (apoptosis)。UBX1325 是一种有效的抗衰老剂,可用于与年龄相关的眼部疾病的研究,如糖尿病性黄斑水肿 (DME)、年龄相关性黄斑变性 (AMD) 和糖尿病性视网膜病变 (DR)。 | |||
T76210 |
POT-4 TFA
|
||
POT-4 TFA (AL-78898A TFA),Compstatin 衍生物,有效抑制补体因子 C3 激活,适应于年龄相关黄斑变性研究。 | |||
T75156L | Bevasiranib sodium | ||
Bevasiranib sodium 是一种siRNA,可沉默产生血管内皮生长因子(VEGF)的基因。VEGF 在脉络膜新生血管形成(choroidal neo-vascularization, CNV)的发病机制中起着关键作用,而CNV 是湿性年龄相关性黄斑变性(wet age-related macular degeneration, wet AMD)的前兆。 | |||
T75156 | Bevasiranib | ||
Bevasiranib 是一种siRNA,可沉默产生血管内皮生长因子(VEGF)的基因。VEGF 在脉络膜新生血管形成(choroidal neo-vascularization, CNV)的发病机制中起着关键作用,而CNV 是湿性年龄相关性黄斑变性(wet age-related macular degeneration, wet AMD)的前兆。 | |||
T36620 |
ALK4290
ALK4290 |
||
ALK4290 (AKST4290) is a potent and orally actively CCR3 inhibitor, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3]. | |||
T69452 |
AG-13958 monohydrochloride
|
||
AG-13958 monohydrochloride is the HCl salt of AG-13958 --- a VEGFA inhibitor potentially for the treatment of age-related macular degeneration. Neovascular AMD, a subtype characterized by the growth of new, pathologic blood vessels, results in most of the cases of severe and rapid vision loss associated with AMD. A critical activator of angiogenesis in neovascular AMD is VEGF. | |||
T13157L |
TG 100801 Hydrochloride
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
TG 100801 Hydrochloride is a prodrug to treat age-related macular degeneration. TG 100572 is a inhibitor of multi-targeted kinase(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, | |||
T74551 |
Avacincaptad pegol sodium
|
||
Avacincaptad pegol (ARC1905) 是一种靶向补体因子5 (C5)的核酸适配体,抑制C5剪切为C5a 和C5b。Avacincaptad pegol 被用于研究与年龄相关的黄斑变性(AMD)。 | |||
T76887 | Rinucumab | ||
Rinucumab (REGN 2176) 是一种单克隆抗体,是PDGF 的抑制剂。Rinucumab (REGN 2176) 可用于新生血管性年龄相关性黄斑变性的研究。 | |||
T76987 | Tarcocimab | ||
Tarcocimab (OG1953) 是一种人源化抗VEGFA 单克隆抗体 (IgG1 型)。Tarcocimab 可用于视网膜静脉阻塞 (RVO) 和湿性老年性黄斑变性 (AMD) 的研究。 | |||
T76814 | Lampalizumab | ||
Lampalizumab (RG 7417) 为靶向补体通路中补体因子 D (Factor D) 的人源单克隆抗体。通过结合外位点,该药物立体阻断因子 B 进入活性位点,用于老年性黄斑变性 (AMD) 研究。 | |||
T74552 | Non-PEGylated/naked ARC1905 | ||
Non-PEGylated/naked ARC1905 是一种没有偶联PEG 的靶向补体因子5 (C5)的核酸适配体,抑制C5剪切为C5a 和C5b。Non-PEGylated/naked ARC1905 被用于研究与年龄相关的黄斑变性(AMD)。 | |||
T79010 | Lp-PLA2-IN-12 | Phospholipase | Metabolism |
Lp-PLA2-IN-12(compound 19)为一种Lp-PLA2抑制剂,主要应用于神经退行性疾病(如AD、青光眼、AMD)及心血管疾病(诸如动脉粥样硬化)的研究。 | |||
T79074 | Lp-PLA2-IN-14 | Phospholipase | Metabolism |
Lp-PLA2-IN-14(Compound 19)是一种选择性的Lp-PLA2抑制剂,其对rhLp-PLA2表现出较高亲和力,pIC50值达到8.4。该化合物主要适用于对抗与神经退行性疾病相关的研究,包括阿尔茨海默病(AD)、青光眼、年龄相关性黄斑变性(AMD),以及心血管疾病如动脉粥样硬化等。 | |||
T63192 | Lp-PLA2-IN-10 | ||
Lp-PLA2-IN-10 是一种有效的脂蛋白相关磷脂酶 A2 (Lp-PLA2) 抑制剂。Lp-PLA2-IN-10 能够用于神经退行性相关疾病的研究,如阿尔茨海默病(AD)、青光眼、年龄相关的黄斑变性 (AMD),或者包括动脉粥样硬化等心血管疾病。Lp-PLA2 曾经被称作血小板活化因子乙酰水解酶 (PAF-AH),是一种参与脂蛋白脂质或磷脂水解的磷脂酶 A2。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T83915 |
Norbixin hydrate
|
||
Norbixin是一种在B. orellana中发现的类胡萝卜素,具有多样的生物活性。在无细胞测试中,它与过氧化物酶体增殖物激活受体γ (PPARγ)结合(Ki = 1.15 µM)。在心脑血管代谢综合征大鼠模型中,Norbixin (47.7 mg/kg) 能够减轻高血糖、高胰岛素血症和胰岛素抗性,降低血清脂质水平及心脏中硫代巴比妥酸反应性物质(TBARS)和谷胱甘肽(GSH)的水平。在胆固醇诱导的动脉粥样硬化兔模型中,它降低氧化型LDL和主动脉蛋白氧化水平,并减少动脉粥样硬化面积。Norbixin(每天0.1和1 mg/kg)减少汞诱导的大鼠肝细胞和白细胞DNA损伤。此外,它还能预防与年龄相关的黄斑变性(AMD)Abca4-/- Rdh8-/-小鼠模型中的光感受器退化。 |